India All Set to Revolutionize Copy Cat Image of Pharmaceutical Industries

Bangalore: India, the South Asian country is one of the world's biggest suppliers of generic drugs. The credit goes to the decade long home based pharmaceutical industries of India that have been both admired and despised for producing low-cost untested western medicines.

The recent breakthrough of the Indian pharmaceutical industry where Zydus Cadilla, a family-owned drug maker with annual revenues of $1 billion, focused on producing diabetes drug, Lipaglyn, based on original research. The new drug is expected to be a ‘blockbuster’ as it is liable to tackle both high blood sugar and cholesterol in a single pill, reported Mark Brierley for NewStatesman.

Last month Zydus had announced that Indian supervisory bodies had approved selling an innovative new diabetes drug in the country in the coming months.  It is the first new chemical entity that had been exclusively discovered and developed in India and also to reach the Indian market. But it will take around 3-5 years and additional $ 150 million for clinical trial to get it approved and introduce for sales in the U.S. and other strict western markets.

“India has benefited for years from the research and development efforts in other countries. Now it’s time for India to give back,” said Pankaj Patel, a trained pharmaceutical scientist, reported The Financial Times.

Also Read: Poverty and Illiteracy: Reasons Why India Is Conned Into Clinical Trials

Also Read: India Continues To Be Hub for Clinical Trials